Bath, UK, 19th June, 2014. Atlas Genetics Ltd (“Atlas” or the “Company”), the diagnostic company developing ultra-rapid point-of-care (POC) tests for a range of infectious diseases, has won the “Best for Innovation” award in the BVCA Management Team Awards 2014 for the South West region.

The prize was given out by the British Private Equity and Venture Capital Association (BVCA), the industry body and public policy advocate for the private equity and venture capital industry in the UK.  The BVCA Management Team Awards are an annual celebration of the best and brightest UK businesses which are supported by private equity and venture capital.  The “Best for Innovation” award aims to recognise the achievements of the management teams of eligible companies in driving innovation.

Atlas Genetics has developed the io system, a highly novel molecular diagnostic system for the ultra-rapid diagnosis of a broad range of infectious diseases including Sexually Transmitted Infections (STIs) and Hospital Acquired Infections (HAIs).  The io system will make it possible, for the first time, to carry out a broad range of infectious disease tests in primary care clinics and GP surgeries that are as accurate as those carried out in hospital laboratories.  This will enable clinicians to test and commence treatment within the same appointment and ensure much improved compliance, particularly in the area of STIs, where a significant proportion of patients fail to return for test results or follow-on treatment.

John Clarkson, CEO of Atlas, said: “I’m delighted that the work of Atlas Genetics has been recognised through this prestigious award.  We are at the forefront of clinical science in the development of fast and accurate tests for infectious diseases.  The ability for clinicians and GPs to diagnose and treat in the same session is important for the prevention of onward transmission of infection.  The underlying technology is based on long term collaborative research with the University of Bath, and this award is testament to the strength of that collaboration and the scale of innovation that it has fostered.”

Bath, UK, 17 June, 2014. Atlas Genetics Ltd (“Atlas” or the “Company”), developer of innovative, ultra-rapid diagnostics to enable a ‘test and treat’ solution to infectious diseases, today announces that the installation and commissioning of its manufacturing line for the Atlas io® Cartridge at Bespak has completed.  The io Cartridge was developed in collaboration with Bespak for use with the Atlas io Reader, which together form a Point of Care system that can deliver laboratory quality results for molecular assays in under thirty minutes.

The io® system is a highly novel molecular diagnostic system for the ultra-rapid diagnosis of a broad range of infectious diseases including Sexually Transmitted Infections (STIs) and Hospital Acquired Infections (HAIs).  It is based on a patent-protected electrochemical sensor technology that combines speed, accuracy and low manufacturing costs. The fully integrated Cartridge contains all reagents on board and is designed to receive an unprocessed clinical specimen.  The Cartridge is then inserted into the Reader which then completes the three-stage process of sample preparation, DNA amplification and electrochemical detection, to analyse the patient’s sample for the target infection.

In addition to deployment in hospital settings, the io system will make it possible, for the first time, to carry out a broad range of infectious disease tests in primary care clinics and GP surgeries that are as accurate as those carried out in hospital laboratories.  This will enable clinicians to test and commence treatment within the same appointment and ensure much improved compliance, particularly in the area of STIs, where a significant proportion of patients fail to return for test results or follow-on treatment.

The manufacturing line for the io® Cartridge has been established within a dedicated purpose-built ISO Class 8 cleanroom at Bespak’s site in Kings Lynn, UK.  The line will use components and reagents from a supply chain of qualified suppliers which has also been established. The io® Cartridge is now entering pilot manufacture to supply Cartridges for validation activities and clinical studies later this year to support the subsequent application for regulatory clearance in Europe early next year. 

The io® Cartridge will initially be available for the diagnosis of Chlamydia, but a pipeline of other tests and combinations are already under development.  The platform has the potential to simultaneously test for up to 24 different diseases on a single Cartridge.

John Clarkson, CEO of Atlas, said: “Manufacturing capability is an important step on the road to regulatory clearance and a significant milestone in the commercial development of our io platform. The establishment of manufacturing at Bespak further differentiates Atlas from other diagnostic companies and will facilitate the future scale-up in capacity for our products.”

Keyvan Djamarani, MD of Bespak, commented “We are very pleased to have completed the industrialisation of the Atlas io Cartridge and to have the manufacturing line operational in King’s Lynn for pilot manufacture, in support of clinical testing for CE mark approval. We are excited by the product and the commercial opportunity which it presents in the Point of Care Testing space.”